Sun H. Kim
Tulane University
19 Papers
243 Citations
Sun H. Kim is an academic researcher from Tulane University. The author has contributed to research in topics: Somatostatin & Growth hormone secretion. The author has an hindex of 10, co-authored 19 publications.
Chat about Author
Papers
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
Ilan Shimon,John E. Taylor,J Z Dong,R A Bitonte,Sun H. Kim,B Morgan,D H Coy,Michael D. Culler,Shlomo Melmed +8 more
TL;DR: Results indicate that SSTR5 is critical for physiologic regulation of GH and TSH, and SRIF analogs with selective affinity for this receptor may therefore be more effective in the treatment of hormone-secreting pituitary adenomas.
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
P. Jaquet,Ginette Gunz,Alexandru Saveanu,H. Dufour,John E. Taylor,J Z Dong,Sun H. Kim,J. P. Moreau,Alain Enjalbert,Michael D. Culler +9 more
TL;DR: Novel dopamine-somatostatin chimeric molecules with differing, enhanced activity at sstr2, sstr5 and DAD2, consistently produced significatly greater suppression of GH and PRL than either octreotide or single-receptor-interacting ligands in tumors from patients classified as only partially responsive toOctreotide therapy.
Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.
Song-Guang Ren,Sun H. Kim,John Taylor,Josse Dong,Jacques-Pierre Moreau,Michael D. Culler,Shlomo Melmed +6 more
TL;DR: The results indicate that mechanisms by which the chimeric molecule suppresses pituitary GH secretion may not be mediated by individual SSTR2 or DAR2 signaling, respectively.
85
•Journal Article
BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
P. Jaquet,G. Gunz,Alexandru Saveanu,Anne Barlier,H. Dufour,J.L. Taylor,Jesse Z. Dong,Sun H. Kim,Jacques-Pierre Moreau,Michael D. Culler +9 more
TL;DR: The comparative efficacy of a somatostatin receptor 1 and 5 subtypes (SSTR2 and SSTR5), and dopamine D2 (DAD2) compound, BIM-23A760, in suppressing GH secretion in cell culture from human GH-secreting tumors, from patients partially responsive to long-term treatments with octreotide or lanreotide is reported.
77
Patent
Somatostatin-dopamine chimeric analogs
Michael D. Culler,Zheng Xin Dong,Sun H. Kim,Jacques-Pierre Moreau +3 more
- 07 Jun 2002
TL;DR: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions as mentioned in this paper.
29